Welcome to the Hawaii Chapter of the American College of Cardiology


2026 Conference
Click here to learn about our annual Chapter meeting April 25, 2026
Click here to download the flyer

ACC Live Courses
For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings


RSS Latest in Cardiology from ACC.org

  • ALERT: Electronic Notifications Improve Management of AS, MR
    Electronic clinician notification alerts were shown to be effective in improving the timely evaluation and treatment of patients with severe aortic stenosis (AS) or mitral regurgitation (MR), according to the ALERT trial presented during a Featured Clinical Research session...
  • CADENCE: Sotatercept Significantly Benefits Patients With CpcPH, HFpEF
    Sotatercept, an activin signaling inhibitor, was associated with significant improvements in blood pressure and vascular health in patients with heart failure with preserved ejection fraction (HFpEF) and severe combined post and precapillary pulmonary hypertension (CpcPH), according to results of the CADENCE study presented during a Late-Breaking Clinical Trial session at ACC.26 in New Orleans and […]
  • SPIRIT-HF: Does Spironolactone Benefit Patients With HFpEF, HFmrEF?
    Spironolactone, an aldosterone blocker, compared with placebo, did not show any significant improvement in terms of heart failure (HF) hospitalizations and cardiovascular death at 24 months in patients with HF with preserved or mildly reduced ejection fraction (HFpEF, HFmrEF), according to results of the SPIRIT-HF trial presented during a Late-Breaking Clinical Trial session at ACC.26 […]
  • SCOUT-HCM: Mavacamten Benefits Adolescents With oHCM
    Mavacamten, a first-in-class drug, was associated with a significant improvement in left ventricular outflow tract (LVOT) gradient compared to placebo in adolescent patients with obstructive hypertrophic cardiomyopathy (oHCM), based on results from the international, multicenter SCOUT-HCM study presented during a Late-Breaking Clinical Trial session at ACC.26 in New Orleans and simultaneously published in NEJM.
  • ALL-RISE: AI-Supported Coronary Flow Assessment Performs Similarly to Gold-Standard Wire-Based Testing
    FFRangio, a minimally invasive, artificial intelligence (AI)-assisted, novel method of measuring fractional flow reserve (FFR), performed similarly to traditional wire-based testing in patients with coronary artery disease (CAD) undergoing assessment for PCI, according to results from the ALL-RISE trial presented during a Late-Breaking Clinical Trial session at ACC.26 in New Orleans and simultaneously published in […]